Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent avian influenza virus-like particle H7N9 + Matrix-M1 adjuvant
- Development stage
- Unknown
- Lead developer
- Novavax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a **combination vaccine** composed of a **monovalent avian influenza H7N9 virus-like particle (VLP)** and the **Matrix-M1 adjuvant**. The VLP mimics the native structure of H7N9 influenza virus but is non-infectious, delivering the hemagglutinin antigen to stimulate an immune response. The Matrix-M1 adjuvant is a nanoparticle-based immunostimulant made from *Quillaja saponaria* saponins, cholesterol, and phospholipids, enhancing both the humoral and cellular immune response. Matrix-M1 adjuvant acts by recruiting and activating antigen-presenting cells in local lymph nodes, broadening and deepening immune responses and providing antigen dose sparing[1][2][3][4][5]. The combination aims to achieve robust protection against avian H7N9 influenza, with the Matrix-M1 adjuvant boosting both antibody and T cell responses[5]. Developed primarily for pandemic prevention, this vaccine is used in clinical trials for influenza protection.
- Other names
- H7N9 VLP with Matrix-M1 adjuvantH-7N9 VLP with Matrix-M1 adjuvantH 7N9 VLP with Matrix-M1 adjuvantH7N9 virus-like particle vaccine + Matrix-M1influenza VLP H7N9 + Matrix-MH7N9 VLP Matrix-M1H-7N9 VLP Matrix-M1H 7N9 VLP Matrix-M1
02
Targets
CD4 (T lymphocyte surface antigen)CD8A (CD8 alpha/beta Coreceptor)HA (Hemagglutinin)
Beyond the preview
Go deeper on monovalent avian influenza virus-like particle H7N9 + Matrix-M1 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent avian influenza virus-like particle H7N9 + Matrix-M1 adjuvant.